Even though xCT silencing did not alter glioma cell growth and proliferation [58], pharmacological inhibition of this transporter with S-4-CPG or SAS significantly reduced the growth of glioblastoma cells in an L-cystine–dependent manner [58, 83]. The gene discussed is SLC7A11; the disease is central nervous system cancer.